Amirghofran Z - Search Results

1

Premature senescence of T lymphocytes from patients with beta-thalassemia major.

Gharagozloo M, Bagherpour B, Tahanian M, Oreizy F, Amirghofran Z, Sadeghi HM, Hourfar H, Moayedi B. Gharagozloo M, et al. Among authors: amirghofran z. Immunol Lett. 2009 Jan 29;122(1):84-8. doi: 10.1016/j.imlet.2008.12.003. Epub 2008 Dec 30. Immunol Lett. 2009. PMID: 19118576

2

Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells.

Gharagozloo M, Amirghofran Z. Gharagozloo M, et al. Among authors: amirghofran z. J Cancer Res Clin Oncol. 2007 Aug;133(8):525-32. doi: 10.1007/s00432-007-0197-x. Epub 2007 Apr 14. J Cancer Res Clin Oncol. 2007. PMID: 17436018

3

Antiphospholipid antibodies and hepatitis C virus infection in Iranian thalassemia major patients.

Kashef S, Karimi M, Amirghofran Z, Ayatollahi M, Pasalar M, Ghaedian MM, Kashef MA. Kashef S, et al. Among authors: amirghofran z. Int J Lab Hematol. 2008 Feb;30(1):11-6. doi: 10.1111/j.1751-553X.2007.00916.x. Int J Lab Hematol. 2008. PMID: 18190462

4

The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine.

Gharagozloo M, Khoshdel Z, Amirghofran Z. Gharagozloo M, et al. Among authors: amirghofran z. Eur J Pharmacol. 2008 Jul 28;589(1-3):1-7. doi: 10.1016/j.ejphar.2008.03.059. Epub 2008 Apr 6. Eur J Pharmacol. 2008. PMID: 18619590

5

Double-faced cell-mediated immunity in beta-thalassemia major: stimulated phenotype versus suppressed activity.

Gharagozloo M, Karimi M, Amirghofran Z. Gharagozloo M, et al. Among authors: amirghofran z. Ann Hematol. 2009 Jan;88(1):21-7. doi: 10.1007/s00277-008-0564-y. Epub 2008 Aug 9. Ann Hematol. 2009. PMID: 18690440

6

Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.

Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z. Gharagozloo M, et al. Among authors: amirghofran z. Fundam Clin Pharmacol. 2009 Jun;23(3):359-65. doi: 10.1111/j.1472-8206.2009.00681.x. Epub 2009 May 7. Fundam Clin Pharmacol. 2009. PMID: 19453758 Clinical Trial.

7

Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production.

Gharagozloo M, Velardi E, Bruscoli S, Agostini M, Di Sante M, Donato V, Amirghofran Z, Riccardi C. Gharagozloo M, et al. Among authors: amirghofran z. Pharmacol Res. 2010 May;61(5):405-9. doi: 10.1016/j.phrs.2009.12.017. Epub 2010 Jan 7. Pharmacol Res. 2010. PMID: 20056147

8

Immunomodulatory effects of silymarin in patients with β-thalassemia major.

Gharagozloo M, Karimi M, Amirghofran Z. Gharagozloo M, et al. Among authors: amirghofran z. Int Immunopharmacol. 2013 Jun;16(2):243-7. doi: 10.1016/j.intimp.2013.04.016. Epub 2013 Apr 26. Int Immunopharmacol. 2013. PMID: 23624215 Clinical Trial.

9

Modulatory effects of thymol and carvacrol on inflammatory transcription factors in lipopolysaccharide-treated macrophages.

Gholijani N, Gharagozloo M, Farjadian S, Amirghofran Z. Gholijani N, et al. Among authors: amirghofran z. J Immunotoxicol. 2016;13(2):157-64. doi: 10.3109/1547691X.2015.1029145. Epub 2015 Mar 27. J Immunotoxicol. 2016. PMID: 25812626 Free article.

10

Modulation of Cytokine Production and Transcription Factors Activities in Human Jurkat T Cells by Thymol and Carvacrol.

Gholijani N, Gharagozloo M, Kalantar F, Ramezani A, Amirghofran Z. Gholijani N, et al. Among authors: amirghofran z. Adv Pharm Bull. 2015 Dec;5(Suppl 1):653-60. doi: 10.15171/apb.2015.089. Epub 2015 Dec 31. Adv Pharm Bull. 2015. PMID: 26793612 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

137 results

Search Page

Filters